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| INTRODUC TI ON
Invasive fungal infections (IFIs) are a leading cause of morbidity in immunocompromised people, including those living with HIV (PLHIV).
1,2 Pathogenic fungi are responsible for a variety of syndromes in PLHIV, such infections can develop into life-threatening conditions. 3 Pneumocystis jirovecii is the most common cause of respiratory infection while Cryptococcus neoformans is a frequently isolated pathogen from central nervous system (CNS) of PLHIV worldwide. 4 Prevalence of other IFIs depends largely on geographic localisation as Histoplasma capsulatum is more frequent in Americas, whereas Talaromyces marneffei (formerly Penicillium marneffei) is common in South and Southeast Asia. Other common IFIs in PLHIV include aspergillosis and candidiasis. Early diagnosis and appropriate antifungal therapy could play a significant role in improving management of patients with IFIs. 5 Encouragingly, early diagnosis and prompt antiretroviral therapy (ART) initiation among PLHIV have significantly decreased the incidence of IFIs. However,
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People living with HIV (PLHIV) are highly vulnerable to invasive fungal infections Herein, we review findings on the merits of BDG assays in the diagnosis of IFIs and monitoring of antifungal therapies for PLHIV. Conversely to other types of immunocompromised patients, HIV infection is associated with gut damage and subsequent bacterial and fungal translocation leading to elevated BDG plasma levels. The utility of the BDG assay in diagnosis of IFIs has been extensively reviewed in general populations with a pooled sensitivity of 76.8% and specificity of 85.3%. 7 However, its use for diagnosis of IFIs in PLHIV remains to be established. In this paper, we review relevant studies which investigated the clinical implications of BDG assays to diagnose IFIs and monitor therapeutic responses to antifungal therapy in both the blood and cerebrospinal fluid (CSF)
of PLHIV. Herein, we searched literature in English language using
PubMed and Google scholar to select publications reported on the merits of BDG in the diagnosis of IFIs in the general population and PLHIV. We limited the search to publications with a sample size of more than 10 PLHIV and for which we could have sensitivity and/or specificity of BDG for the diagnosis of IFIs.
| APPLI C ATI ON OF B DG A S A D IAG NOS TI C AND MONITORING TOOL FOR IFIS IN PLHIV
(1→3)-β-d-glucan has been used for the diagnosis of IFIs including P. jirovecii pneumonia (PJP), Cryptococcosis and others in PLHIV, as summarised in Table 1 . PJP is a common HIV-infected opportunistic infection caused by P. jirovecii. 18 The standard method to diagnose PJP requires visualisation of P. jirovecii cysts in microscopic examination of respiratory secretions such as bronchoalveolar lavage fluid or lung biopsy samples. Both of these techniques require severely invasive procedures for definitive diagnosis. 19 We describe studies reporting BDG as a diagnostic tool for PJP in PLHIV.
The first reporting of serum BDG sensitivity for PJP diagnosis was in 2007 by Fujii et al 20 , which showed a sensitivity of 97% using kits from Japan. Later studies using Fungitell test with different cutoff values showed a sensitivity ranging from 90% to 100% and specificity ranging from 65% to 96.4% 21, 22 (Table 1 ). In addition, the study suggested that increasing the cut-off value for the diagnosis of PJP as compared to the diagnosis of invasive aspergillosis or invasive candidiasis could improve the specificity of the test. similarly, using the cut-off value of 23.2 pg/mL, Watanabe et al 23 Few studies had evaluated the value of BDG in monitoring treatment response of IFIs in PLHIV. 23, 24 A study using Fungitec G MK test failed to find any correlation between disease severity and BDG levels.
This indicates that the assay may not be useful for therapeutic monitoring of PJP. 23 Another study showed that positive BDG result is probable 
TA B L E 1 Deployment of BDG as a diagnosis tool of IFIs in HIV-infected patients
in any given patient with CM, particularly amongst those with severe conditions. 24 Therefore, CSF BDG assay could be used as a monitoring tool for the response to antifungal therapy among patients with CM.
| B DG A S A PL A S MA LE VEL B I OMARK ER OF MICROB IAL TR ANS LOC ATION
In HIV-negative people, the specificity of BDG test is compromised in the presence of factors that could increase BDG levels for reasons other than IFI. This includes haemodialysis with cellulose membranes, administration of human blood products (immunoglobulins or albumin), use of antibiotics such as amoxicillin-clavulanate or piperacillintazobactam, presence of serious bacterial infections, use of surgical gauzes containing glucan, or severe mucositis. 7 In PLHIV, it may be further limited as recent evidences showed BDG may be also a surrogate marker of microbial translocation in asymptomatic people.
From the early phase of HIV infection to a chronic state, substantial immunological and structural disruption occurs in the gastrointestinal tract. This leads to microbial translocation and subsequently contributes to systematic immune activation. [28] [29] [30] Gut "microbial translocation" is defined as the non-physiological passage of the gastrointestinal microflora or their products through the intestinal epithelial barrier into circulating blood. 31 Markers of bacterial translocation Therefore, to differentiate from microbial translocation, a higher cutoff value is required to improve the specificity of IFIs in PLHIV, which warrants further investigation. Meanwhile, it is critical to take other laboratory tests (e.g. microbial results and radiology profiles) into consideration to rule in IFIs in asymptomatic PLHIV with elevated BDG level. In some cases, monitoring the dynamic of BDG may also be necessary. 
